Summary
PSC Chart
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026
Mirum Pharmaceuticals, Inc. retains a Buy rating, supported by positive interim analyses for VOLIXIBAT in both PBC [VANTAGE] and PSC [VISTAS] phase 2b trials. Key catalysts include VISTAS topline data in Q2 2026, VANTAGE topline data in H1 2027, and phase 3 EXPAND enrollment completion in 2026. Company strengthened its balance sheet with $200M gross proceeds from Bluejay Therapeutics acquisition and private placements, plus a $68.5M TCGX placement agreement.
Principal U.S. Small-Cap ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 2.46M | $125.27M | $167.32M | $42.06M | 33.57% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 178,518 | $12.52M | $12.52M | - | - |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 612 | $35,079.84 | $35,079.84 | - | - |
 Richard Zito Flynn Zito Capital Management LLC | 75,022 | $4.64M | $5.11M | $466,260.68 | 10.04% |
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 7,454 | $522.71 | $522.71 | - | - |
Principal U.S. Small-Cap ETF (PSC) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Principal U.S. Small-Cap ETF Profile
| NASDAQ (NMS) Exchange | US Country |
Overview
The focus of this fund is to invest predominantly in equity securities, specifically targeting U.S. companies that have small market capitalizations at the time of purchase. The determination of small market capitalizations is aligned with the range of companies that are included within the Russell 2000 Index. This strategy is maintained by allocating at least 80% of the fund's net assets, in addition to any leverage derived from borrowings for investment purposes, into these smaller companies. Such an investment approach underscores a commitment to harnessing the growth potential of small-cap U.S. companies, aiming to capitalize on the unique opportunities they present.
Products and Services
- Equity Securities Investment
This service focuses on investing in the equity securities of U.S. companies with small market capitalizations. By targeting companies within the Russell 2000 Index range, the fund seeks to capitalize on the growth potential of these smaller entities, balancing risk with the prospects of significant returns.
- Leveraged Investment Strategies
Beyond its equity investments, the fund takes advantage of leveraged investment strategies by using borrowings for investment purposes. This approach allows the fund to amplify its investment capacity, enhancing its potential for higher returns while also increasing risk exposure.
